We're rapidly approaching the end of 2012 and, while initial public offerings for tech companies usually grab the headlines, the health care space also had a number of exciting IPOs this year. Not all of them were winners, but Tesaro (NASDAQ: TSRO) is up more than 16% year to date (as of the writing of this article). In the following video, health care analysts Max Macaluso and Brenton Flynn discuss Tesaro's business and drug pipeline.
Let's look at Tesaro's business and drug pipeline.
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo